Efinaconazole is a triazole antifungal and 14α-demethylase inhibitor. The compound was synthesized as an azoleamine derivative (Kaken Phermaceutical Co). The fungal lanosterol 14α-demethylase is involved in the conversion of lanosterol to ergosterol thus it impacts fungal morphology. Ergosterol is a structural compound which maintains membrane fluidity, creates a permability barrier, and is needed for fungal cell viability. Efinaconazole has activity against Trichophyton rubrum and T. mentagrophytes, two dematophytes that cause onychomycosis. Efinaconazole is sparingly soluble in DMSO.
